ALACHUA, Fla., Sept. 25, 2014 (GLOBE NEWSWIRE) -- via PRWEB - AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral nerve repair market, reported attendance at two recent surgeon education events exceeded management's expectations and registration at two upcoming professional education seminars is near capacity. The event at the American Society for Surgery of the Hand (ASSH) in Boston, held this past week, drew surgeons interested in nerve repair in the upper extremity from the US and multiple other countries. Surgeons focused on repair of the trigeminal nerve in the lower jaw attended an event at the American Association of Oral and Maxillofacial Surgeons (AAOMS) annual meeting in Hawaii.
The strong interest reflects the market's need for AxoGen's portfolio of nerve repair products: Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. The Company's efforts to build market awareness for its disruptive off-the-shelf products, through education and a growing body of clinical evidence, is driving adoption of its products and the significant sales growth AxoGen experienced in the first half of 2014. The Company is sponsoring two additional professional education events in the fourth quarter and, based on the current enrollment trends, attendance is already near capacity.
"The strong momentum generated by our team during the second quarter has continued into the third quarter," said Karen Zaderej, President and Chief Executive Officer. "Our peer-to-peer education events are becoming increasingly popular as surgeons seek alternatives to traditional nerve repair techniques. By highlighting the latest science and best practices in surgical nerve repair, surgeons can embrace our comprehensive portfolio of products enabling them to experience the benefits and positive impacts these can have on their patients and practice. On average, these surgeons perform 80-100 nerve repair surgeries annually and these education opportunities are increasing interest in our product lines and expanding usage within our customer base."
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/09/prweb12198331.htm